Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.

Advances in Targeting Signal Transduction Pathways / J.A. McCubrey; L.S. Steelman; W.H. Chappell; L. Sun; N.M. Davis; S.L. Abrams; R.A. Franklin; L. Cocco; C. Evangelisti; F. Chiarini; A.M. Martelli; M. Libra; S. Candido; G. Ligresti; G. Malaponte; M.C. Mazzarino; P. Fagone; M. Donia; F. Nicoletti; J. Polesel; R. Talamini; J. Bäsecke; S. Mijatovic; D. Maksimovic-Ivanic; M. Milella; A. Tafuri; J. Dulińska-Litewka; P. Laidler; A. B. D’Assoro; L. Drobot ; K. Umezawa; G. Montalto; M. Cervello; Z. N. Demidenko.. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 3:(2012), pp. 1505-1521.

Advances in Targeting Signal Transduction Pathways.

COCCO, LUCIO ILDEBRANDO;C. Evangelisti;MARTELLI, ALBERTO MARIA;
2012

Abstract

Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.
2012
Advances in Targeting Signal Transduction Pathways / J.A. McCubrey; L.S. Steelman; W.H. Chappell; L. Sun; N.M. Davis; S.L. Abrams; R.A. Franklin; L. Cocco; C. Evangelisti; F. Chiarini; A.M. Martelli; M. Libra; S. Candido; G. Ligresti; G. Malaponte; M.C. Mazzarino; P. Fagone; M. Donia; F. Nicoletti; J. Polesel; R. Talamini; J. Bäsecke; S. Mijatovic; D. Maksimovic-Ivanic; M. Milella; A. Tafuri; J. Dulińska-Litewka; P. Laidler; A. B. D’Assoro; L. Drobot ; K. Umezawa; G. Montalto; M. Cervello; Z. N. Demidenko.. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 3:(2012), pp. 1505-1521.
J.A. McCubrey; L.S. Steelman; W.H. Chappell; L. Sun; N.M. Davis; S.L. Abrams; R.A. Franklin; L. Cocco; C. Evangelisti; F. Chiarini; A.M. Martelli; M. Libra; S. Candido; G. Ligresti; G. Malaponte; M.C. Mazzarino; P. Fagone; M. Donia; F. Nicoletti; J. Polesel; R. Talamini; J. Bäsecke; S. Mijatovic; D. Maksimovic-Ivanic; M. Milella; A. Tafuri; J. Dulińska-Litewka; P. Laidler; A. B. D’Assoro; L. Drobot ; K. Umezawa; G. Montalto; M. Cervello; Z. N. Demidenko.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/134056
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 37
social impact